Primary Myelofibrosis Market Insights, Epidemiology and Market Forecast - 2028

Publisher Name :
Date: 15-Apr-2019
No. of pages: 120
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Primary Myelofibrosis - Market Insights, Epidemiology and Market Forecast - 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain and the United Kingdom)

- Japan

Study Period: 2017-2028

Primary Myelofibrosis Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Primary Myelofibrosis in the US, Europe, and Japan are also provided in the report.

Primary Myelofibrosis Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Primary Myelofibrosis Product Profiles & Analysis

This part of the Primary Myelofibrosis report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Primary Myelofibrosis Market Outlook

The Primary Myelofibrosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Primary Myelofibrosis Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Primary Myelofibrosis Report Insights

- Patient Population in Primary Myelofibrosis

- Therapeutic Approaches in Primary Myelofibrosis

- Primary Myelofibrosis Pipeline Analysis

- Primary Myelofibrosis Market Size and Trends

- Primary Myelofibrosis Market Opportunities

- Impact of upcoming Therapies in Primary Myelofibrosis

Primary Myelofibrosis Report Key Strengths

- 10 Year Forecast

- 7MM Coverage

- Epidemiology Segmentation

- Drugs Uptake

- Highly Analyzed Market

- Key Cross Competition

Primary Myelofibrosis Report Assessment

- Current Treatment Practices in Primary Myelofibrosis

- Unmet Needs in Primary Myelofibrosis

- Detailed Primary Myelofibrosis Pipeline Product Profiles

- Market Attractiveness

- Market Drivers and Barriers

Key Benefits

- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Primary Myelofibrosis market

- Organize sales and marketing efforts by identifying the best opportunities for Primary Myelofibrosis market

- To understand the future market competition in the Primary Myelofibrosis market.

Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the client by providing the most up to date Report. It usually takes 7-10 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Primary Myelofibrosis Market Insights, Epidemiology and Market Forecast - 2028

Table of Contents

1. Report Introduction
2. Primary Myelofibrosis Market Overview at a Glance
2.1. Market Share Distribution of Primary Myelofibrosis in 2018
2.2. Market Share Distribution of Primary Myelofibrosis in 2028
3. Disease Background and Overview: Primary Myelofibrosis
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Primary Myelofibrosis in 7MM
4.3. Total Prevalent Patient Population of Primary Myelofibrosis in 7MM - By Countries
5. Epidemiology of Primary Myelofibrosis by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Primary Myelofibrosis
5.1.3. Sub-Type Specific cases of the Primary Myelofibrosis *Indication Specific
5.1.4. Sex- Specific Cases of the Primary Myelofibrosis*Indication Specific
5.1.5. Diagnosed Cases of the Primary Myelofibrosis
5.1.6. Treatable Cases of the Primary Myelofibrosis
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Primary Myelofibrosis
5.4.3. Sub-Type Specific cases of the Primary Myelofibrosis*
5.4.4. Sex- Specific Cases of the Primary Myelofibrosis*
5.4.5. Diagnosed Cases of the Primary Myelofibrosis
5.4.6. Treatable Cases of the Primary Myelofibrosis
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Primary Myelofibrosis
5.5.3. Sub-Type Specific cases of the Primary Myelofibrosis*
5.5.4. Sex- Specific Cases of the Primary Myelofibrosis*
5.5.5. Diagnosed Cases of the Primary Myelofibrosis
5.5.6. Treatable Cases of the Primary Myelofibrosis
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Primary Myelofibrosis
5.6.3. Sub-Type Specific cases of the Primary Myelofibrosis*
5.6.4. Sex- Specific Cases of the Primary Myelofibrosis*
5.6.5. Diagnosed Cases of the Primary Myelofibrosis
5.6.6. Treatable Cases of the Primary Myelofibrosis
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Primary Myelofibrosis
5.7.3. Sub-Type Specific cases of the Primary Myelofibrosis*
5.7.4. Sex- Specific Cases of the Primary Myelofibrosis*
5.7.5. Diagnosed Cases of the Primary Myelofibrosis
5.7.6. Treatable Cases of the Primary Myelofibrosis
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Primary Myelofibrosis
5.8.3. Sub-Type Specific cases of the Primary Myelofibrosis*
5.8.4. Sex- Specific Cases of the Primary Myelofibrosis*
5.8.5. Diagnosed Cases of the Primary Myelofibrosis
5.8.6. Treatable Cases of the Primary Myelofibrosis
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Primary Myelofibrosis
5.9.3. Sub-Type Specific cases of the Primary Myelofibrosis*
5.9.4. Sex- Specific Cases of the Primary Myelofibrosis*
5.9.5. Diagnosed Cases of the Primary Myelofibrosis
5.9.6. Treatable Cases of the Primary Myelofibrosis
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Primary Myelofibrosis
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies - At a glance
10. Key Cross Competition
11. Emerging Therapies for Primary Myelofibrosis
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Primary Myelofibrosis: 7MM Market Analysis
12.1. 7MM Market Size of Primary Myelofibrosis
12.2. 7MM Percentage Share of drugs marketed for Primary Myelofibrosis
12.3. 7MM Market Sales of Primary Myelofibrosis by Products
13. Primary Myelofibrosis: Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Primary Myelofibrosis in United States
13.1.2. Percentage Share of drugs marketed for Primary Myelofibrosis in United States
13.1.3. Market Sales of Primary Myelofibrosis by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Primary Myelofibrosis in Germany
13.2.1.2. Percentage Share of drugs marketed for Primary Myelofibrosis in Germany
13.2.1.3. Market Sales of Primary Myelofibrosis by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Primary Myelofibrosis in France
13.2.2.2. Percentage Share of drugs marketed for Primary Myelofibrosis in France
13.2.2.3. Market Sales of Primary Myelofibrosis by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Primary Myelofibrosis in Italy
13.2.3.2. Percentage Share of drugs marketed for Primary Myelofibrosis in Italy
13.2.3.3. Market Sales of Primary Myelofibrosis by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Primary Myelofibrosis in Spain
13.2.4.2. Percentage Share of drugs marketed for Primary Myelofibrosis in Spain
13.2.4.3. Market Sales of Primary Myelofibrosis by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Primary Myelofibrosis in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Primary Myelofibrosis in United Kingdom
13.2.5.3. Market Sales of Primary Myelofibrosis by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Primary Myelofibrosis in Japan
13.3.2. Percentage Share of drugs marketed for Primary Myelofibrosis in Japan
13.3.3. Market Sales of Primary Myelofibrosis by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Tables

Table 1: Total Prevalent/Incident Cases of the Primary Myelofibrosis in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Myelofibrosis in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Myelofibrosis in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Primary Myelofibrosis in United States (2017-2028)
Table 5: Sex- Specific Cases of the Primary Myelofibrosis in United States (2017-2028)
Table 6: Diagnosed Cases of the Primary Myelofibrosis in United States (2017-2028)
Table 7: Treatable Cases of the Primary Myelofibrosis in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Primary Myelofibrosis in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Primary Myelofibrosis in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Primary Myelofibrosis in Germany (2017-2028)
Table 11: Diagnosed Cases of the Primary Myelofibrosis in Germany (2017-2028)
Table 12: Treatable Cases of the Primary Myelofibrosis in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Primary Myelofibrosis in France (2017-2028)
Table 14: Sub-Type Specific cases of the Primary Myelofibrosis in France (2017-2028)
Table 15: Sex- Specific Cases of the Primary Myelofibrosis in France (2017-2028)
Table 16: Diagnosed Cases of the Primary Myelofibrosis in France (2017-2028)
Table 17: Treatable Cases of the Primary Myelofibrosis in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Primary Myelofibrosis in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Primary Myelofibrosis in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Primary Myelofibrosis in Italy (2017-2028)
Table 21: Diagnosed Cases of the Primary Myelofibrosis in Italy (2017-2028)
Table 22: Treatable Cases of the Primary Myelofibrosis in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Primary Myelofibrosis in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Primary Myelofibrosis in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Primary Myelofibrosis in Spain (2017-2028)
Table 26: Diagnosed Cases of the Primary Myelofibrosis in Spain (2017-2028)
Table 27: Treatable Cases of the Primary Myelofibrosis in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Primary Myelofibrosis in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Primary Myelofibrosis in UK (2017-2028)
Table 30: Sex- Specific Cases of the Primary Myelofibrosis in UK (2017-2028)
Table 31: Diagnosed Cases of the Primary Myelofibrosis in UK (2017-2028)
Table 32: Treatable Cases of the Primary Myelofibrosis in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Primary Myelofibrosis in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Primary Myelofibrosis in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Primary Myelofibrosis in Japan (2017-2028)
Table 36: Diagnosed Cases of the Primary Myelofibrosis in Japan (2017-2028)
Table 37: Treatable Cases of the Primary Myelofibrosis in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Table 42:7MM- Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Table 45: United States-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Table 48: Germany-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Table 51: France-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Table 54: Italy-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Table 57: Spain-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Table 60:UK-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Table 63: Japan-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Primary Myelofibrosis in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Myelofibrosis in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Myelofibrosis in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Primary Myelofibrosis in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Primary Myelofibrosis in United States (2017-2028)
Figure 6: Diagnosed Cases of the Primary Myelofibrosis in United States (2017-2028)
Figure 7: Treatable Cases of the Primary Myelofibrosis in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Primary Myelofibrosis in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Primary Myelofibrosis in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Primary Myelofibrosis in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Primary Myelofibrosis in Germany (2017-2028)
Figure 12: Treatable Cases of the Primary Myelofibrosis in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Primary Myelofibrosis in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Primary Myelofibrosis in France (2017-2028)
Figure 15: Sex- Specific Cases of the Primary Myelofibrosis in France (2017-2028)
Figure 16: Diagnosed Cases of the Primary Myelofibrosis in France (2017-2028)
Figure 17: Treatable Cases of the Primary Myelofibrosis in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Primary Myelofibrosis in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Primary Myelofibrosis in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Primary Myelofibrosis in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Primary Myelofibrosis in Italy (2017-2028)
Figure 22: Treatable Cases of the Primary Myelofibrosis in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Primary Myelofibrosis in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Primary Myelofibrosis in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Primary Myelofibrosis in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Primary Myelofibrosis in Spain (2017-2028)
Figure 27: Treatable Cases of the Primary Myelofibrosis in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Primary Myelofibrosis in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Primary Myelofibrosis in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Primary Myelofibrosis in UK (2017-2028)
Figure 31: Diagnosed Cases of the Primary Myelofibrosis in UK (2017-2028)
Figure 32: Treatable Cases of the Primary Myelofibrosis in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Primary Myelofibrosis in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Primary Myelofibrosis in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Primary Myelofibrosis in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Primary Myelofibrosis in Japan (2017-2028)
Figure 37: Treatable Cases of the Primary Myelofibrosis in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Figure 42:7MM- Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Figure 45: United States-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Figure 48: Germany-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Figure 51: France-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Figure 54: Italy-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Figure 57: Spain-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Figure 60:UK-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Primary Myelofibrosis in USD MM (2017-2028)
Figure 63: Japan-Market Share Primary Myelofibrosis by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Primary Myelofibrosis by Therapies in USD MM (2017-2028)
  • Global Pemetrexed Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Aug-2019        Price: US 3480 Onwards        Pages: 123
    Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer. Scope of the Report: The worldwide market for Pemetrexed is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Pem......
  • Global Drug Integrated Polymer Fibers Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Aug-2019        Price: US 3480 Onwards        Pages: 103
    Drug integrated polymer fibers are used to create implantable textile devices using a combination of resorbable as well as non-resorbable polymers. These devices can be made from different materials and are available in custom sizes and shapes to meet specific biological requirements. With a rise in complexity along with technological innovations, textile devices are being designed to meet a broader range of applications than earlier which will boost the demand of drug integrated polymer fibers.......
  • Global Fast-dissolving Tablets Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Aug-2019        Price: US 3480 Onwards        Pages: 123
    Fast-dissolving Tablets is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken. Sc......
  • Global Fast-disintegrating Tablets Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Aug-2019        Price: US 3480 Onwards        Pages: 118
    Fast-disintegrating Tablets is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken. ......
  • Global Rapid-dissolving Tablets Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Aug-2019        Price: US 3480 Onwards        Pages: 122
    Rapid-dissolving Tablets is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken. S......
  • Global Mouth-dissolving Tablets Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Aug-2019        Price: US 3480 Onwards        Pages: 122
    Mouth-dissolving Tablets is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken. S......
  • Global Orodispersible Tablets Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 23-Aug-2019        Price: US 3480 Onwards        Pages: 117
    An Orodispersible Tablets is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole. The ODT serves as an alternative dosage form for patients who experience dysphagia (difficulty in swallowing) or for where compliance is a known issue and therefore an easier dosage form to take ensures that medication is taken. ......
  • Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights, Trends and Forecast (2019-2028)
    Published: 22-Aug-2019        Price: US 1600 Onwards        Pages: 96
    The global Non-Alcoholic Steatohepatitis (NASH) drugs market is expected to reach US$61.60 billion in 2028, growing at a CAGR of 39.36%, for the duration spanning 2018-2028. The factors such as rising prevalence of NASH, increasing diabetic population, rising obesity, unmet medical needs and sedentary lifestyle are expected to drive the growth of the market. However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic me......
  • Global (United States, European Union and China) Endometriosis Market Research Report 2019-2025
    Published: 22-Aug-2019        Price: US 3280 Onwards        Pages: 121
    Endometriosis is a medical condition in which the tissue that forms normal lining of uterus appears outside the uterus cavity and may involve ovaries, bowel or tissue lining of the pelvic floor. Rising incidences of endometriosis due to diagnostic improvements leading to early identification, environmental factors, and rising awareness is the key factor contributing to growth of the market. Global endometriosis market is expected to register a healthy growth, owing to rise in awareness am......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs